

PAXLOVID USE

For more information,
please visit this FAQ from the FDA

On May 25, 2023, Paxlovid was FDA approved for treatment of mild-to-moderate coronavirus disease (COVID-19) in adults who are high risk for progression to severe COVID-19, including hospitalization or death.

A Boxed Warning was added to Paxlovid's full prescribing information to ensure providers evaluate patients closely for possible significant drug-drug interactions.

The EUA still authorizes the *emergency* use of Paxlovid in pediatric patients (12-17 years old weighing at least 40 kg). Paxlovid has not yet been fully FDA approved in pediatrics.

Paxlovid is neither FDA-approved nor authorized for emergency use for pre-exposure or post-exposure prophylaxis for prevention of COVID-19.

The Paxlovid EUA continues to authorize the government purchased supply of Paxlovid for EMERGENCY use in adults in addition to pediatric patients.

This ensures continued access for all eligible patients to the U.S. government's supply of Paxlovid pending commercial launch of the approved product.

The use of Paxlovid under the EUA must be consistent with the terms and conditions of the authorization.